Closing the Gender Gap in Oncology Academic Leadership: Reshma Jagsi, MD, DPhil
Sarah Williams, MAT
Expert Analysis
​A recent study by Mudit Chowdhary, MD, and colleagues revealed that a substantial gender gap remains in academic oncology leadership: in a web query of 265 of the 273 accredited medical, radiation, and surgical oncology training programs, only 35.9% of faculty members were women. Representation was substantially lower among department chairs, with...
E-Cigarettes and Bladder Cancer Risk: Marc Bjurlin, DO, MSc
Keira Smith
Expert Analysis
Despite their known pulmonary, neurological, and carcinogenic risks, electronic cigarette (e-cigarette) use has increased drastically in recent years, especially among adolescents and young adults. In a recent study, a team of researchers led by Marc Bjurlin, DO, MSc, Associate Professor of Urology at the University of North Carolina Chapel Hill's ...
COVID-19 Risk in Cancer Patients: Melvin LK Chua, MBBS, FRCR, PhD, and Conghua Xie, MD, PhD
Sarah Williams, MAT
Expert Analysis
Last week, a research team under the direction of Conghua Xie, MD, PhD, and Melvin LK Chua, MBBS, FRCR, PhD, reported in JAMA Oncology that patients with cancer at a hospital in Wuhan, China, experienced an increased risk of COVID-19 infection relative to other members of the community. In this interview with i3 Health, Dr. Chua and Dr. Xie discuss...
Head and Neck Cancer: Reducing In-Hospital Mortality With Eric Adjei Boakye, PhD
Sarah Williams, MAT
Expert Analysis
​Over 4% of head and neck cancer (HNC) patients who are hospitalized die during their stay in the hospital. How can this number be reduced? In a cross-sectional study recently published in JAMA Otolaryngology—Head and Neck Surgery, a research team led by Eric Adjei Boakye, PhD, found that among a variety of other patient- and hospital-related facto...
Expanding Later-Line Treatment Options for Multiple Myeloma: Paul G. Richardson, MD
Sarah Williams, MAT
Expert Analysis
Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior lines of treatment, including lenalidomide and a proteasome inhibitor. In this interview with i3 Health, Paul G. Richa...
Metastatic Colorectal Cancer: Treatment Challenges, Progress, and Advice With Chiara Cremolini, MD
Emily Levitch
Expert Analysis
Colorectal cancer is the third leading cause of cancer death and the fourth most common diagnosed cancer in the world. Often, this disease is left undiagnosed until it reaches an advanced stage. Unfortunately, late-stage metastatic colorectal cancer has a poor prognosis with a 5-year survival rate of only 12%. In an interview with i3 Health, Chiara...
FOLFOXIRI Efficacy in Metastatic Colorectal Cancer: Chiara Cremolini, MD
Emily Levitch
Expert Analysis
Results of TRIBE2, a phase 3 trial (NCT02339116), show that the triplet treatment FOLFOXIRI (fluorouracil/leucovorin/oxaliplatin/irinotecan) plus bevacizumab is more effective at treating patients with metastatic colorectal cancer than FOLFIRI (irinotecan/leucovorin/fluorouracil) plus bevacizumab. In an interview with i3 Health, Chiara Cremolini, M...
Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: Alison Birtle, MD
Keira Smith
Expert Analysis
Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a mortality rate of over 50% for locally advanced disease. However, few clinical trials have been conducted due to its low incidence rate. Nephroureterectomy—a surgical procedure in which the renal pelvis, kidney, ureter, and bladder cuff are removed—is considered the standard t...
Milk and Breast Cancer Risk: Gary E. Fraser, MBChB, PhD
Sarah Williams, MAT
Expert Analysis
​United States Dietary Guidelines recommend that adults and children aged 9 or older consume three cups per day of low-fat or fat-free milk and dairy foods, or alternatively, three cups of calcium-fortified soymilk. However, a large observational study recently published in the International Journal of Epidemiology reports that consuming three...
Neratinib: Progress for HER2-Positive Metastatic Breast Cancer With Adam Brufsky, MD, PhD, FACP
Sarah Williams, MAT
Expert Analysis
Last week, the FDA added a second approval for neratinib (Nerlynx​®​, Puma Biotechnology, Inc.) in combination with capecitabine for adults with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer previously treated with at least two anti-HER2–based regimens in the metastatic setting. This adds to the previous approval o...
Nadofaragene Firadenovec in Non–Muscle-Invasive Bladder Cancer: Colin Dinney, MD
Sarah Williams, MAT
Expert Analysis
​High-grade non–muscle-invasive bladder cancer that does not respond to intravesical Bacillus Calmette-Guerin (BCG) therapy carries a substantial risk of disease recurrence and progression, and effective salvage intravesical therapies are sorely needed for patients who are unable or unwilling to undergo cystectomy. According to results of a multice...
RNF43 Variation and Cetuximab Efficacy in Metastatic Colorectal Cancer: Francesca Battaglin, MD
Sarah Williams, MAT
Expert Analysis
​In metastatic colorectal cancer, there has been a concerted effort to identify biomarkers that can predict the efficacy of existing treatments and support the development of new targeted therapies. As part of these efforts, Francesca Battaglin, MD, and colleagues investigated the association between cetuximab efficacy and gene expression levels an...
Resecting Non–Contrast-Enhancing Tumor in Glioblastoma: Mitchel Berger, MD
Sarah Williams, MAT
Expert Analysis
​In patients with newly diagnosed glioblastoma, maximal extent of surgical resection of contrast-enhancing tumor has consistently been associated with benefits to survival. However, in a practice-changing study published recently in JAMA Oncology, a team of investigators under the leadership of Mitchel Berger, MD, found that extending resection to ...
HSD3B1 Genotype and Prostate Cancer Outcomes: Nima Sharifi, MD
Sarah Williams, MAT
Expert Analysis
Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invariably becomes castration resistant. A new analysis of data from the phase 3 CHAARTED trial, published last week in JAMA Oncology, shows that men with low-volume metastatic CSP...
Baseline Liver Function As a Prognostic Factor in Unresectable HCC: Arndt Vogel, MD
Keira Smith
Expert Analysis
In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepatocellular carcinoma (HCC). However, the assessment of baseline liver function as a prognostic factor for patients with unresectable HCC receiving lenvatinib had not yet been inve...
Enhancing Treatment for Patients With GIST: Michael Heinrich, MD
Sarah Williams, MAT
Expert Analysis
Because gastrointestinal stromal tumor (GIST) has an estimated incidence of 3,300 to 6,000 new cases per year in the United States, comprising less than 1% of all gastrointestinal tumors, the rarity of this tumor type can make it more challenging for oncologists and other members of the cancer care team to stay up to date on the latest treatments. ...
How Genetic Testing Results Impact Breast Cancer Treatment: Allison Kurian, MD, MSc
Sarah Williams, MAT
Expert Analysis
​With our ever-growing understanding of mutations that increase cancer risk and the rise of targeted treatments such as poly (ADP-ribose) polymerase (PARP) inhibitors that are indicated for specific mutations, the use of germline genetic testing for patients with breast cancer has increased significantly in recent years. How are these test results ...
The Current State of CRPC Management With Judd W. Moul, MD, FACS
Devi Seal
Expert Analysis
In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still remain. In this interview with i3 Health, Judd W. Moul, MD, FACS, Professor of Urologic Surgery at the Duke School of Medicine, di...
Avapritinib for PDGFRA Exon 18-Mutated GIST: Michael Heinrich, MD
Sarah Williams, MAT
Expert Analysis
Up to 10% of patients with gastrointestinal stromal tumor (GIST) harbor platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, which have been linked to resistance to standard GIST therapies. The FDA's recent approval of avapritinib (AyvakitTM, Blueprint Medicines) for adults with unresectable or metastatic GIST with PDGFRA exon ...
Pembrolizumab for Non-Muscle Invasive Bladder Cancer With Ashish Kamat, MD, MBBS
Keira Smith
Expert Analysis
The FDA recently approved pembrolizumab (Keytruda®, Merck) for the treatment of patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) therapy. The approval was based on Keynote 057 (NCT02625961), a phase 2 trial in which pembrolizumab produced a complete response rate of 41% in patients wi...

Copyright © 2022 Oncology Data Advisor. All rights reserved.